LifeMD, Inc.
No enriched coverage for $LFMD in the last 7 days.
No SEC Form 4 filings for $LFMD in the last 30 days.
LifeMD, Inc. (LFMD) has awarded its Chief Financial Officer, Atul Kavthekar, 337,500 restricted stock units (RSUs) as part of a compensation grant. These RSUs were granted at a price of $0.00 per share and will vest in three equal tranches on March 16, 2027, March 16, 2028, and March 16, 2029, aligning his compensation with multi-year service. Following this grant, Kavthekar directly holds 337,500 shares.
Jump Financial LLC increased its stake in LifeMD, Inc. (NASDAQ:LFMD) by 205.0% in the second quarter, acquiring an additional 346,171 shares, bringing its total holdings to 515,052 shares valued at $7,015,000. Other institutional investors like Connor Clark & Lunn, Geode Capital Management, and JPMorgan Chase also adjusted their positions in the telehealth company. Despite mixed analyst ratings, with six firms issuing a Buy and one a Hold, the stock has a consensus "Hold" rating and an average target price of $9.25.
HIMS expands into low testosterone and menopause care, with plans for longevity and global growth in 2026.
